FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

Why did Trump end trade talks with Canada? How will Nike’s tariff impact affect profits? What caused Nvidia’s surging stock price? Why is the Fed hesitant to cut rates? How is AI changing corporate workforce roles? What’s behind the US-China rare earths deal? Why are stablecoin startups attracting record VC funding?

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

benzinga.com/news/fda/25/06/46144447/fda-eases-rules-for-bristol-myers-cell-therapies-for-blood-cancers

The U.S. Food and Drug Administration (FDA) approved label updates for Bristol Myers Squibb & Co.’s (NYSE:BMY) CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for large B cell lymphoma (LBCL) and other lymphomas and Abecma (idecabtagene vicleucel; ide-cel) for multiple…

This story appeared on benzinga.com, 2025-06-27 15:34:09.